Filing Flows › Innoviva (INVA) › Recalls, complaints & regulation
Innoviva (INVA): clinical trials
Innoviva (INVA) beyond its filings: 2 active clinical trials.
Innoviva's latest quarter
Innoviva, Q3 2026: revenue $106M (-2% year over year), operating margin 39.7%, net loss $73.9M, operating cash flow $41.7M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Innoviva have?
2 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.